Peer-reviewed veterinary case report
Oral docetaxel and cyclosporin A treatment tested in cats with tumors
By McEntee, M C et al.·Published in Journal of veterinary internal medicine·2006·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats.
- Species:
- cat
Plain-English summary
Eighteen cats with tumors were given a combination of oral docetaxel (a chemotherapy drug) and cyclosporin A to see how well they could tolerate it and how the drugs behaved in their bodies. The starting dose of docetaxel was 1.0 mg/kg, and the maximum safe dose was found to be 1.75 mg/kg, but some cats experienced gastrointestinal issues and blood-related side effects. While the study focused on safety and dosage, further research is needed to see how effective this treatment is for cats with certain types of tumors.
People also search for: cat tumor treatment · docetaxel for cats · chemotherapy side effects in cats
Abstract
Intravenously administered docetaxel (DT) is problematic in cats because of the requirement for premedication to ameliorate acute vehicle-induced hypersensitivity reactions. Previously we have revealed that therapeutic plasma concentrations of DT can be achieved in normal and tumor-bearing dogs when DT is administered PO in combination with oral cyclosporin A (CSA). The purpose of this study was to identify the maximally tolerated dosage and characterize the pharmacokinetic disposition of oral DT combined with CSA in cats with tumors. Eighteen tumor-bearing cats were enrolled in this phase I dose escalation and pharmacokinetic study. DT was administered by gavage with CSA (5 mg/kg) twice over a 3-week period. The starting dose of DT was 1.0 mg/kg. Based on the clinical toxicity profile, with gastrointestinal adverse effects and hematologic toxicity the maximal tolerated dose of oral DT was 1.75 mg/kg in combination with 5 mg/kg CSA. Additional studies are necessary to determine the efficacy of DT/CSA in cats with epithelial tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17186852/